Where Will Illumina, Inc. (ILMN) Stock Go Next After It Is Lower By 3.28% in a Week?

Illumina, Inc. (ILMN) stock is lower by 3.28% over the past week and gets a Bearish rating from InvestorsObserver Sentiment Indicator.

Illumina, Inc. has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on ILMN!

See Full ILMN Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With ILMN Stock Today?

Illumina, Inc. (ILMN) stock is lower by -0.2% while the S&P 500 has gained 0.04% as of 1:32 PM on Friday, Sep 24. ILMN has fallen -$0.85 from the previous closing price of $433.20 on volume of 441,397 shares. Over the past year the S&P 500 has risen 37.50% while ILMN has gained 58.37%. ILMN earned $5.20 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 83.04. To screen for more stocks like Illumina, Inc. click here.

More About Illumina, Inc.

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates revenue from sequencing tools and dedicated consumables (76% of 2020 sales). Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications. Services account for 16% of sales and include basic maintenance services, clinical lab applications (such as noninvasive prenatal, oncology, and rare-disease screening), and whole genome sequencing. Click Here to get the full Stock Report for Illumina, Inc. stock.